| Bioactivity | Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer[1]. |
| Invitro | Surzebiclimab (BGB-A425; 0.1-100 μg/mL) 有效阻断 Tim-3 和 PtdSer 之间的相互作用。Surzebiclimab 增强原代 T 细胞的 IFN-γ 产生和 NK 介导的对肿瘤细胞的细胞毒性[1]。Surzebiclimab 单独或与抗 PD-1 抗体 BGB-A317 联合使用可增强 T 细胞对同种异体抗原的反应。Surzebiclimab 还可以诱导细胞表面 Tim-3 受体的内化[1]。 |
| In Vivo | surzebiclimb (BGB-A425) 联合 BGB-A317 在小鼠异种移植瘤模型中抑制肿瘤生长[1]。 |
| Name | Surzebiclimab |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tong Z, et, al. Abstract 2628: BGB-A425: a humanized anti-human Tim-3 antibody that exhibits strong immune cell activation. Cancer Res. 2017;77:(13_Supplement):2628. |